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p85a neomorphic mutants: splitting away
from the canonical path
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PIK3R1 (encoding the p85a subunit of phosphatidylinositol 3-kinase) is the 11th most frequently mutated gene
across tumors. We recently reported neomorphic p85a mutants that induce signaling cascades not predicted by the
canonical functions of p85a, suggesting the need to functionally annotate speciﬁc mutations in cancer genes for
effective genome-informed personalized therapy.
Class 1A phosphoinositide 3-kinase
(PI3K) is a heterodimeric lipid kinase com-
posed of a p85 regulatory subunit and
p110 catalytic subunit that activates pro-
tein kinase B (AKT) and other downstream
effectors. Aberrations of components of the
PI3K pathway are collectively the most
common activating events in cancers.
PIK3R1 (encoding p85a, which has been
proposed to be the critical regulator of
p110) is also frequently mutated; indeed,
PIK3R1 is the 11th most commonly
mutated gene across cancer lineages in The
Cancer Genome Atlas database.1 Previ-
ously characterized PIK3R1 mutations
exclusively target PI3K pathway activation.
We and others have demonstrated several
hypomorphic (decrease in function)
PIK3R1 mutations that activate the PI3K
pathway by relieving the inhibition of
p110a or by destabilizing phosphatase and
tensin homolog (PTEN) protein.2,3 In a
recent study, we described an unexpected
neomorphic (gain of novel function) role
for a subset of PIK3R1 mutations derived
from cancer patients.4 This subset of muta-
tions, including R348* and neighboring
truncation mutations, represents the most
common recurrent PIK3R1 mutations,
accounting for approximately 10% of all
PIK3R1 mutations in endometrial and
colon cancers and therefore justifying the
exploration of approaches able to benefit
patients with these aberrations.
Our first step leading to the neomorph
concept was an unbiased drug screen with
a library of 150 compounds targeting
major signaling pathways. The data
revealed that the p85a neomorphs ren-
dered cells sensitive to mitogen-activated
protein kinase kinase (MEK) and c-Jun
N-terminal protein kinases (JNK) inhibi-
tors. This was completely unexpected
because p85a does not normally impinge
on the mitogen-activated protein kinase
(MAPK) pathway. In support of these
data, wild-type p85a and other known
oncogenic p85a mutants had no effect on
sensitivity to the MEK and JNK inhibi-
tors. We next undertook functional prote-
omics analysis of the mutants through a
reverse phase protein array that covers
proteins of cancer-relevant signaling path-
ways. In complete accord with the drug
sensitivity data, the neomorphs, but not
wild-type or other p85a mutants, induced
phosphorylation of extracellular signal
regulated kinase (ERK) and JNK, indicat-
ing that activation of the pathway under-
lies drug sensitivity. Subsequent
mechanistic studies revealed that the neo-
morphs resulted in selective activation of
components of the ERK and JNK signal-
ing cascades.
The activation of MAPK pathways by
the neomorphs is independent of the con-
ventional role of p85a in PI3K signaling.
First, the activation was insensitive to
PI3K inhibitors. Second, the truncation
mutation produces a protein that cannot
bind to p110, and thus the neomorphic
activity is unlikely to be mediated through
p110. This p110-independency and the
lack of intrinsic kinase activity of p85a
led to the major question of how the neo-
morphs activate MAPK pathways, and
particularly nuclear JNK. Strikingly, we
discovered that, in contrast to wild-type
p85a, the neomorphs were present in the
nucleus where they acted as a scaffold to
tether JNK signaling components in close
proximity thereby facilitating JNK activa-
tion. This distinct neomorphic character-
istic compared with wild-type p85a and
the other p85amutants is probably attrib-
utable to the p85a protein domains pres-
ent that lead to differential binding
partners (Fig. 1). The neomorphs were
translocated into the nucleus by binding
to nuclear transport chaperones including
the small GTPases cell division cycle 42
(Cdc42) and Ras-related C3 botulinum
toxin substrate 1 (Rac1) through the intact
p85a breakpoint-cluster region homology
(BH) domain. Although wild-type p85a
and some other p85a mutants contain the
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BH domain, and indeed bind these
nuclear chaperones, their nuclear import
is prohibited, possibly because of physical
linkage to cytoskeletal and membrane pro-
teins mediated by the src homology 2
(SH2) domains.
p85a that is not bound to p110 can
undergo homodimerization that may alter
the conformation of the protein, thus
exposing motifs that bind specific sets of
proteins. We have demonstrated that the
wild-type p85a homodimer binds and
stabilizes PTEN.2 This binding was dis-
rupted in a truncated mutant E160* lack-
ing the BH and SH2 domains, which does
not translocate into the nucleus or alter
the catalytic activity of p110. Therefore,
homodimerization resulting from p85a
truncation proteins of different sizes may
alter the binding partners. Given that the
neomorphs do not bind p110, whether
the neomorphic effects are mediated by a
homodimer or by a heterodimeric form of
the mutant with wild-type p85a remains
to be investigated.
Our observations that xenograft
tumors expressing neomorphs were sus-
ceptible to MAPK inhibitors and that
endometrial cancer patients bearing neo-
morphs had high levels of ERK and JNK
phosphorylation may provide a rationale
for therapeutic targeting of these mutant
tumors. These mutations could potentially
be biomarkers of responsiveness to inhibi-
tors targeting the ERK and JNK path-
ways. Since the neomorphs also activate
the PI3K pathway4 and activation of the
MAPK pathway by Ras mutants can
mediate resistance to therapy targeting the
PI3K pathway,5 it may be necessary to
treat patients with these neomorphs using
a combination of MEK and PI3K path-
way inhibitors. A combinatorial approach
of MEK and PI3K pathway inhibition is
being assessed in several clinical trials for
colon cancer and endometrial cancer
patients.
More importantly, our identification
and characterization of neomorphs consti-
tutes an important conceptual advance
suggesting that targeted
therapies may need to be
conditioned on the specific
aberration in the cancer
gene rather than on the can-
cer gene alone. To date,
neomorphic mutations have
also been reported in IDH1,
IDH2, and TP53.6,7 Func-
tional characterization of
patient-specific mutations
may be needed to fulfill the
promise of personalized can-
cer therapy and, impor-
tantly, prevent untoward
consequences of targeted
therapy. This is especially
true for genes that are linked
to specific targeted thera-
pies. Identification and
characterization of neo-
morphs is particularly chal-
lenging because available approaches to
predict the function of mutations, includ-
ing protein structure modeling, may have
limited robustness for neomorphic
actions. The experimental pipeline estab-
lished in this study is a proof-of-concept
that can be implemented in other func-
tional genomics studies.
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